BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more
BioNxt Solutions Inc. (BNXTF) - Total Assets
Latest total assets as of September 2025: $1.23 Million USD
Based on the latest financial reports, BioNxt Solutions Inc. (BNXTF) holds total assets worth $1.23 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioNxt Solutions Inc. - Total Assets Trend (2018–2024)
This chart illustrates how BioNxt Solutions Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioNxt Solutions Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
BioNxt Solutions Inc.'s total assets of $1.23 Million consist of 28.8% current assets and 71.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.7% |
| Accounts Receivable | $60.60K | 10.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how BioNxt Solutions Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioNxt Solutions Inc.'s current assets represent 28.8% of total assets in 2024, an increase from 27.7% in 2018.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2024, down from 26.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
BioNxt Solutions Inc. Competitors by Total Assets
Key competitors of BioNxt Solutions Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
BioNxt Solutions Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioNxt Solutions Inc. generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioNxt Solutions Inc. is currently not profitable relative to its asset base.
BioNxt Solutions Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.22 | 0.04 | 2.28 |
| Quick Ratio | 0.22 | 0.04 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.06 Million | $ -7.82 Million | $ 1.58 Million |
BioNxt Solutions Inc. - Advanced Valuation Insights
This section examines the relationship between BioNxt Solutions Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.77 |
| Latest Market Cap to Assets Ratio | 60.58 |
| Asset Growth Rate (YoY) | -55.1% |
| Total Assets | $569.36K |
| Market Capitalization | $34.49 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BioNxt Solutions Inc.'s assets at a significant premium ( 60.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: BioNxt Solutions Inc.'s assets decreased by 55.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioNxt Solutions Inc. (2018–2024)
The table below shows the annual total assets of BioNxt Solutions Inc. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $569.36K | -55.08% |
| 2023-12-31 | $1.27 Million | -21.40% |
| 2022-12-31 | $1.61 Million | -83.42% |
| 2021-12-31 | $9.73 Million | +17.41% |
| 2020-12-31 | $8.28 Million | -4.29% |
| 2019-12-31 | $8.66 Million | -3.09% |
| 2018-12-31 | $8.93 Million | -- |